Join
Live feed
·
PRReleasevia Quantisnow
EyePoint Inc. logo

EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration

ByQuantisnow·Wall Street's wire, on your screen.
EYPT· EyePoint Inc.
Industrials
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EYPT (EyePoint Inc.) and more on Quantisnow.